Bruker Corporation Website

Bruker Corporation

NasdaqGS-BRKR

Company Overview

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

  • Name

    Bruker Corporation

  • CEO

    Frank H. Laukien

  • Website

    www.bruker.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1960

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Bruker Corporation Surges with Strong Orders and Analyst Support

  • Significant orders totaling approximately $25 million for high-performance magnetic resonance systems from European research institutions bolster investor confidence.
  • Analyst upgrades, including a Buy rating from Rothschild & Co Redburn, enhance positive market sentiment towards Bruker.
  • Mixed reactions to board changes and cautious financial management practices create isolated bearish indicators but do not significantly impact overall performance.

Over the past month, Bruker Corporation (BRKR) demonstrated strong stock performance, appreciating by 12.5%. This increase notably outperformed the S&P 500's return of just 0.7%, resulting in an overperformance of 11.8% relative to the index. Additionally, Bruker's performance surpassed that of the Health Care sector (XLV), which gained only 2.1%, marking a significant outperformance of 10.6%.

A major catalyst for this bullish momentum was the announcement on December 10th regarding substantial orders worth approximately $25 million for advanced magnetic resonance systems from three leading European research institutions. These contracts are expected to contribute meaningfully to revenue recognition in fiscal years 2026 and 2027, reinforcing expectations for future growth.

Analyst activity further supported Bruker's stock trajectory during this period as Rothschild & Co Redburn initiated coverage with a Buy rating and set a price target at $60 per share. Barclays also raised its price objective from $40 to $45 while maintaining an overweight rating on December 10th. Despite Goldman Sachs initiating coverage with a Sell rating and setting a lower price target at $40 earlier in December, overall analyst sentiment remained optimistic about Bruker’s prospects.

However, some bearish indicators emerged throughout the month that temporarily affected investor sentiment. On December 8th, Jack Phillips' appointment to Bruker's board generated mixed reactions concerning strategic direction in diagnostics technology development despite being overshadowed by positive news surrounding new contracts and analyst ratings. Furthermore, although the company declared a quarterly dividend alongside stagnant annual increases reflecting cautious financial management practices after exceeding earnings expectations in their latest report.

Bruker Corp outperformed the Health Care (XLV) sector by 10.6%.

NasdaqGS:BRKR